If you’ve ever wondered why that prescription you filled six months ago still works as intended, or why generic drugs remain effective for years after manufacturing, the answer lies in stability studies—an unsung backbone of the Active Pharmaceutical Ingredients (API) space, and a practice I’ve centered my work on for nearly 12 years as an API supplier. When I first started in this field, I thought quality was just about making a pure, potent API; over time, I’ve learned it’s about making that API reliably potent and safe, no matter how it’s stored, shipped, or sits on a shelf. Stability studies aren’t a one-and-done regulatory box-check—they’re the blueprint that keeps patients and partners trusting the products we supply. Let me walk through what these studies actually entail, why they matter, and how we integrate them into every layer of our API operations. Active Pharmaceutical Ingredients
To start, let’s ground this in a basic truth an API supplier lives by: APIs are the core of every drug, and their chemical, physical, and biological properties can shift over time if not properly managed. A single API molecule might degrade, react with moisture, or change shape (crystallize) if conditions are off, turning a safe, effective product into one that’s less potent or even harmful. Stability studies are the rigorous set of tests we run to map these changes, define safe storage conditions, and set shelf lives—all to meet strict regulatory standards from the FDA, ICH, EMA, and other global bodies that oversee drug manufacturing.
Not all stability studies are the same, though. The biggest distinction you’ll hear in our labs is between real-time stability studies and accelerated stability studies. These two work hand in hand, but they serve different purposes. Real-time stability is the gold standard, the one that gives us the shelf life we put on every COA (Certificate of Analysis) we send to our customers. Here, we take finished API batches, package them exactly as they’ll be shipped or stored—think sealed, light-resistant drums, moisture-barrier bags, or climate-controlled containers—and place them in dedicated stability chambers that mimic real-world conditions: typical room temperature (25°C/77°F) and 60% relative humidity (RH), for most APIs. For thermally sensitive APIs, we use long-term conditions like 2°C to 8°C (refrigerated) or -20°C, if needed.
We pull samples at scheduled intervals—initial (before placement), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, and sometimes beyond, depending on regulatory requirements—and run a full battery of tests: potency assays to confirm our API is still within 98-102% of its labeled strength, purity checks to catch any new degradation byproducts, physical testing (like dissolution rate or particle size distribution), and biological testing if the API is a biologic or has inherent activity. Last year, we ran real-time stability for a oncology API our client was developing for a pediatric trial, and after 18 months, we saw a tiny but consistent rise in a single degradation byproduct—less than 0.1% above our initial baseline. That feedback let us adjust our packaging slightly to add an extra moisture barrier, which kept that byproduct well within regulatory limits for the full 24-month shelf life we claimed. Real-time stability is slow (it takes years to get final shelf life data), but it’s the data our partners count on to bring their drugs to market, so we never cut corners here.
Accelerated stability studies, on the other hand, are our predictive tool. These run at harsher conditions—usually 40°C/104°F and 75% RH—for 6 months. The logic here is that stressing the API speeds up any degradation, so we can get preliminary shelf life data much faster, while also flagging issues before they become problems in real-time testing. Accelerated data lets us catch red flags early: if an API degrades 10 times faster at 40°C than at 25°C, that tells us it’s highly temperature-sensitive, and we need to prioritize better cold-chain shipping or storage recommendations for our customers. Two years ago, we ran accelerated stability for a respiratory API that initially looked stable in early testing, but at 40°C, it lost 12% of its potency in just 3 months. That meant we couldn’t market it as a standard-room-temperature API—we redesigned its packaging to include desiccants and added cold-chain notes, which kept our client from launching a product that would fail in field conditions. Accelerated studies aren’t a replacement for real-time data, but they save us and our partners months, even years, of downstream headaches.
Beyond these core two, there are specialized stability studies that cover edge cases regulators demand, especially for APIs with unique properties. One of the most critical is stress testing, sometimes called forced degradation testing. This is where we intentionally break the API on purpose to learn how it reacts to extreme conditions—exposing it to high heat, extreme pH (acidic or alkaline environments), UV light, oxidation, and even hydrolysis (reaction with water). For each stress, we measure what degradation byproducts form, how quickly, and how they behave. This isn’t just curiosity: stress testing helps us validate our analytical methods (can we tell the difference between the original API and a byproduct?), and it lets us develop degradation pathways to predict how the API might react if it’s accidentally exposed to a shipping delay in a hot truck, or a storage area with excess humidity. Last quarter, we ran stress testing on a new antiviral API we just scaled up, and found it breaks down when exposed to trace amounts of hydrogen peroxide, a common sanitizer used in manufacturing facilities. That let us adjust our in-house cleaning protocols and add a note to our packaging specs to avoid peroxide-based sanitizers—something that never would have come up without intentional stress testing.
Another specialized type is transportation stability testing, which we tailor to how our API actually moves around the world. For APIs shipped to Asia, we test for extreme tropical heat by holding samples at 45°C for 10 days (the equivalent of a trans-Pacific shipment in summer), and for APIs going to Europe or North America, we include temperature cycling—fluctuating between 5°C and 30°C over 24 hours, mimicking a warehouse that’s not perfectly climate-controlled. We also test for mechanical stress: vibration from cargo ships or trucks, impact from loading, even stacking weight for palletized shipments. A few years back, a client had a shipment of a bulk antibiotic API arrive with a 3% potency drop, and they couldn’t figure out why. We ran transportation stability tests that matched their shipping route, and found the pallets had been stacked 5 layers high, when our original spec allowed only 3. That feedback let us update our shipping guidelines to clearly label maximum stack weight, and we added secondary labels on each drum to prevent over-stacking—saving our client from a repeat issue.
As an API supplier, we don’t just run these studies in our lab and send the data off to regulators. We integrate stability data into every stage of our operations, because that’s how we earn long-term trust from our partners. For example, when we develop a new API, we start stability testing as soon as we have our first lab-scale batch, not after we’ve already scaled up to commercial production. That gives us time to adjust our formulation, packaging, or storage processes before we invest in large-scale manufacturing. If a new API has a short shelf life, we’ll work with our client to adjust their manufacturing timeline, or recommend a formulation that combines it with other APIs that are more stable, to extend the overall shelf life of their drug product. We also update stability data throughout the lifecycle of an API—if we change a raw material supplier, or a packaging component, we run mini-stability studies to confirm the change doesn’t affect the API’s stability, before implementing it. Regulators call this “continuing stability,” and it’s a requirement, but for us, it’s how we ensure every batch we ship is identical in quality to the first.
It’s also important to note that stability studies aren’t just for regulatory compliance—they’re a patient safety issue. Every API we supply is used to make drugs that treat chronic conditions like diabetes, cancer, or heart disease, where a small change in potency or purity can have life-threatening consequences. A few years ago, we had a client switch to a new API supplier that cut corners on stability testing, and they experienced a batch of their drug failing potency tests mid-shelf life. The recall affected over 10,000 patients, and the client almost lost their FDA approval. That story stuck with me: stability studies aren’t something we do to get a certificate, they’re something we do to protect the patients who rely on the drugs we help make. At our company, every stability study is overseen by a dedicated stability team with 15 years of combined experience, and all our chambers are calibrated monthly, with backup generators to prevent data loss if there’s a power outage. We even have a secondary stability facility in a different part of the country, so if one chamber fails, we can move samples without disrupting testing.
If you’re a pharmaceutical manufacturer, biotech startup, or drug developer looking for API supply, understanding stability studies matters for more than just regulatory paperwork. The shelf life of your final drug, its safety profile, its ability to withstand shipping delays, and your ability to meet regulatory timelines all depend on the stability data of the API you use. As an API supplier, we don’t just provide APIs—we provide stability data that lets you get your drug to market faster, at lower cost, and with less risk. Our stability programs are aligned with ICH Q1A (R2), the global guideline for stability testing of new drug substances and products, and we’ve had zero regulatory observations related to stability data in audits with the FDA and EMA over the past 7 years.
If you’re evaluating API suppliers for your next project, or you’re looking to resolve stability-related challenges with your existing API supply, we invite you to reach out to our team to discuss your needs. We work with partners across therapeutic areas—from oncology and immunology to rare diseases and generic drugs—and can provide customized stability data, packaging recommendations, and ongoing support to ensure your API remains stable from manufacturing to patient administration.
Dietary Supplements References:
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A (R2): Stability Testing of New Drug Substances and Products, 2003.
- U.S. Food and Drug Administration. Guidance for Industry: Stability Testing of Drug Substances and Products, 2003.
- European Medicines Agency. Guideline on Stability Testing of Active Substances, 2006.
- Pikal, M. J. The Importance of Stability Testing in Pharmaceutical Development. Journal of Pharmaceutical Sciences, vol. 91, no. 3, 2002, pp. 615–629.
- Yu, L. X. Mechanistic Understanding of Degradation Pathways in Active Pharmaceutical Ingredients. Advanced Drug Delivery Reviews, vol. 58, no. 14, 2006, pp. 1513–1524.
Xi’an Ruichi Biotech Co., Ltd.
As one of the most professional active pharmaceutical ingredients manufacturers and suppliers in China, we’re featured by quality products and low price. Please rest assured to buy discount active pharmaceutical ingredients in stock here from our factory. Contact us for pricelist.
Address:
E-mail: Jenny@ruichibio.com
WebSite: https://www.ruichibio.com/
